DiaMedica FY2023: $52.9M cash, ReMEDy2 interim enrollment Q1 2025, CMO hired

DiaMedica Therapeutics Inc.

Cash and investments $52.9M at Dec 31, 2023, up from $33.5M; net cash used in ops $18.7M.
R&D expenses $13.1M (up 68% YoY) due to in-use studies and DM199 manufacturing; G&A $8.2M (up 32%).
ReMEDy2 Phase 2/3 trial: 6 U.S. sites open; interim enrollment of 144 patients expected by Q1 2025.
Protocol modified to focus on moderate AIS (NIHSS 5-15) and exclude posterior strokes to boost efficacy.
Appointed Dr. Lorianne Masuoka as CMO in Jan 2024 and Rebekah de Vitry Fries as VP Clinical Operations.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 19, 2024, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2023.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-008521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.